Skip to main content

Table 4 Correlation of candidate circRNAs relative expression with clinical characteristics

From: Comprehensive profiling of circular RNA expressions reveals potential diagnostic and prognostic biomarkers in multiple myeloma

Items

CircRNAs

PTK2

ATIC

RNF217

RERE

SETD5

NAGPA

KCNQ5

CSPP1

SFMBT2

UGGT2

High

High

High

High

High

High

High

High

High

High

Age, No. (%)

 < 60 years

16 (53.3)

15 (50.0)

14 (46.7)

14 (46.7)

14 (46.7)

13 (43.3)

16 (53.3)

16 (53.3)

16 (53.3)

18 (60.0)

 ≥ 60 years

14 (46.7)

15 (50.0)

16 (53.3)

16 (53.3)

17 (56.7)

17 (56.7)

14 (46.7)

14 (46.7)

14 (46.7)

12 (40.0)

 P value

0.606

1.000

0.606

0.606

0.438

0.302

0.606

0.606

0.606

0.121

Gender, No. (%)

 Male

17 (45.9)

13 (56.5)

9 (39.1)

11 (47.8)

14 (60.9)

20 (54.1)

19 (51.4)

20 (54.1)

19 (51.4)

18 (48.6)

 Female

13 (56.5)

17 (45.9)

21 (56.8)

19 (51.4)

17 (45.9)

10 (43.5)

11 (47.8)

10 (43.5)

11 (47.8)

12 (52.2)

 P value

0.426

0.426

0.184

0.791

0.261

0.426

0.791

0.426

0.791

0.791

Immunoglobulin subtype, No. (%)

 IgG

13 (40.6)

15 (46.9)

15 (46.9)

16 (50.0)

18 (56.3)

18 (56.3)

17 (53.1)

19 (59.4)

12 (37.5)

13 (40.6)

 IgA

7 (50.0)

7 (50.0)

9 (64.3)

4 (28.6)

7 (50.0)

8 (57.1)

4 (28.6)

5 (35.7)

8 (57.1)

9 (64.3)

 IgM

1 (100.0)

1 (100.0)

1 (100.0)

1 (100.0)

0 (0.0)

0 (0.0)

1 (100.0)

0 (0.0)

0 (0.0)

1 (100.0)

 IgD

2 (100.0)

1 (50.0)

1 (50.0)

2 (100.0)

1 (50.0)

1 (50.0)

1 (50.0)

2 (100.0)

2 (100.0)

0 (0.0)

 Bence-Jones protein

7 (63.6)

6 (54.5)

4 (36.4)

7 (63.6)

5 (45.5)

3 (27.3)

7 (63.6)

4 (36.4)

8 (72.7)

7 (63.6)

 P value

0.293

0.875

0.544

0.172

0.822

0.398

0.341

0.193

0.109

0.193

Bone lesion, No. (%)

 No

9 (50.0)

8 (44.4)

11 (61.1)

7 (38.9)

10 (55.6)

10 (55.6)

10 (55.6)

11 (61.1)

7 (38.9)

7 (38.9)

 Yes

21 (50.0)

22 (52.4)

19 (45.2)

23 (54.8)

21 (50.0)

20 (47.6)

20 (47.6)

19 (45.2)

23 (54.8)

23 (54.8)

 P value

1.000

0.573

0.260

0.260

0.693

0.573

0.573

0.260

0.260

0.260

Hb, No. (%)

  < 10 g/dL

14 (51.9)

12 (44.4)

14 (51.9)

14 (51.9)

16 (59.3)

14 (51.9)

15 (55.6)

17 (63.0)

13 (48.1)

11 (40.7)

  ≥ 10 g/dL

16 (48.5)

18 (54.5)

16 (48.5)

16 (48.5)

15 (45.5)

16 (48.5)

15 (45.5)

13 (39.4)

17 (51.5)

19 (57.6)

 P value

0.795

0.436

0.795

0.795

0.287

0.795

0.436

0.069

0.795

0.194

Calcium, No. (%)

  < 11.5 mg/dL

21 (50.0)

22 (52.4)

18 (42.9)

17 (40.5)

21 (50.0)

19 (45.2)

20 (47.6)

20 (47.6)

20 (47.6)

22 (52.4)

  ≥ 11.5 mg/dL

9 (50.0)

8 (44.4)

12 (66.7)

13 (72.2)

10 (55.6)

11 (61.1)

10 (55.6)

10 (55.6)

10 (55.6)

8 (44.4)

 P value

1.000

0.573

0.091

0.024

0.693

0.260

0.573

0.573

0.573

0.573

Scr, No. (%)

  < 2 mg/dL

25 (52.1)

26 (54.2)

23 (47.9)

22 (45.8)

26 (54.2)

26 (54.2)

24 (50.0)

26 (54.2)

23 (47.9)

25 (52.1)

  ≥ 2 mg/dL

5 (41.7)

4 (33.3)

7 (58.3)

8 (66.7)

5 (41.7)

4 (33.3)

6 (50.0)

4 (33.3)

7 (58.3)

5 (41.7)

 P value

0.519

0.197

0.519

0.197

0.438

0.197

1.000

0.197

0.519

0.519

ALB, No. (%)

  < 3.5 mg/dL

10 (52.6)

12 (63.2)

7 (36.8)

10 (52.6)

11 (57.9)

12 (63.2)

5 (26.3)

6 (31.6)

8 (42.1)

8 (42.1)

  ≥ 3.5 mg/dL

20 (48.8)

18 (43.9)

23 (56.1)

20 (48.8)

20 (48.8)

18 (43.9)

25 (61.0)

24 (58.5)

22 (53.7)

22 (53.7)

 P value

0.781

0.165

0.165

0.781

0.511

0.165

0.012

0.052

0.405

0.405

β2-MG, No. (%)

  < 5.5 mg/L

11 (32.4)

16 (47.1)

16 (47.1)

16 (47.1)

17 (50.0)

20 (58.8)

15 (44.1)

17 (50.0)

15 (44.1)

16 (47.1)

  ≥ 5.5 mg/L

19 (73.1)

14 (53.8)

14 (53.8)

14 (53.8)

14 (53.8)

10 (38.5)

15 (57.7)

13 (50.0)

15 (57.7)

14 (53.8)

 P value

0.002

0.602

0.602

0.602

0.768

0.118

0.297

1.000

0.297

0.602

LDH, No. (%)

  < 220 U/L

23 (48.9)

21 (44.7)

25 (53.2)

25 (53.2)

24 (51.1)

25 (53.2)

25 (53.2)

25 (53.2)

22 (46.8)

23 (48.9)

  ≥ 220 U/L

7 (53.8)

9 (69.2)

5 (38.5)

5 (38.5)

7 (53.8)

5 (38.5)

5 (38.5)

5 (38.5)

8 (61.5)

7 (53.8)

 P value

0.754

0.117

0.347

0.347

0.859

0.347

0.347

0.347

0.347

0.754

Durie-Salmon stage, No. (%)

 I/II

16 (47.1)

17 (50.0)

15 (44.1)

13 (38.2)

15 (44.1)

16 (47.1)

14 (41.2)

16 (47.1)

18 (52.9)

21 (61.8)

 III

14 (53.8)

13 (50.0)

15 (57.7)

17 (65.4)

16 (61.5)

14 (53.8)

16 (61.5)

14 (53.8)

12 (46.2)

9 (24.6)

 P value

0.602

1.000

0.297

0.037

0.181

0.602

0.118

0.602

0.602

0.037

ISS stage, No. (%)

 I/II

11 (32.4)

16 (47.1)

16 (47.1)

16 (47.1)

17 (50.0)

20 (58.8)

15 (44.1)

17 (50.0)

15 (44.1)

16 (47.1)

 III

19 (73.1)

14 (53.8)

14 (53.8)

14 (53.8)

14 (53.8)

10 (38.5)

15 (57.7)

13 (50.0)

15 (57.7)

14 (53.8)

 P value

0.002

0.602

0.602

0.602

0.768

0.118

0.297

1.000

0.297

0.602

t (4; 14), No. (%)

 No

25 (46.3)

27 (50.0)

27 (50.0)

26 (48.1)

28 (51.9)

28 (51.9)

26 (48.1)

28 (51.9)

27 (50.0)

27 (50.0)

 Yes

5 (83.3)

3 (50.0)

3 (50.0)

4 (66.7)

3 (50.0)

2 (33.3)

4 (66.7)

2 (33.3)

3 (50.0)

3 (50.0)

 P value

0.085

1.000

1.000

0.389

0.931

0.389

0.389

0.389

1.000

1.000

t (14; 16), No. (%)

 No

27 (50.9)

26 (49.1)

27 (50.9)

28 (52.8)

27 (50.9)

26 (49.1)

27 (50.9)

27 (50.9)

27 (50.9)

28 (52.8)

 Yes

3 (42.9)

4 (57.1)

3 (42.9)

2 (28.6)

4 (57.1)

4 (57.1)

3 (42.9)

3 (42.9)

3 (42.9)

2 (28.6)

 P value

0.688

0.688

0.688

0.228

0.758

0.688

0.688

0.688

0.688

0.228

Del (17p), No. (%)

 No

25 (45.5)

28 (50.9)

27 (49.1)

28 (50.9)

26 (47.3)

27 (49.1)

26 (47.3)

29 (52.7)

27 (49.1)

30 (54.5)

 Yes

5 (100.0)

2 (40.0)

3 (60.0)

2 (40.0)

5 (100.0)

3 (60.0)

4 (80.0)

1 (20.0)

3 (60.0)

0 (0.0)

 P value

0.020

0.640

0.640

0.640

0.024

0.640

0.161

0.161

0.640

0.020

Items

    

CircRNAs

     

AFF2

WWC3

SLAIN1

WDR37–1

WDR37–2

DNAJC5

KLHL2

IQGAP1

AL137655

ASAP1

High

High

High

High

High

High

High

High

High

High

Age, No. (%)

  < 60 years

12 (40.0)

15 (50.0)

13 (43.3)

17 (56.7)

15 (50.0)

11 (36.7)

16 (53.3)

15 (50.0)

12 (40.0)

12 (40.0)

  ≥ 60 years

18 (60.0)

15 (50.0)

17 (56.7)

13 (43.3)

16 (53.3)

19 (63.3)

14 (46.7)

15 (50.0)

18 (60.0)

18 (60.0)

 P value

0.121

1.000

0.302

0.302

0.796

0.039

0.606

1.000

0.121

0.121

Gender, No. (%)

 Male

11 (47.8)

18 (48.6)

12 (52.2)

13 (56.5)

10 (43.5)

13 (56.5)

19 (51.4)

20 (54.1)

19 (51.4)

21 (56.8)

 Female

19 (51.4)

12 (52.2)

18 (48.6)

17 (45.9)

21 (56.8)

17 (45.9)

11 (47.8)

10 (43.5)

11 (47.8)

9 (39.1)

 P value

0.791

0.791

0.791

0.426

0.317

0.426

0.791

0.426

0.791

0.184

Immunoglobulin subtype, No. (%)

 IgG

17 (53.1)

15 (46.9)

13 (40.6)

12 (37.5)

18 (56.3)

18 (56.3)

15 (46.9)

17 (53.1)

17 (53.1)

16 (50.0)

 IgA

8 (57.1)

7 (50.0)

10 (70.4)

9 (64.3)

7 (50.0)

5 (35.7)

9 (64.3)

10 (71.4)

7 (50.0)

6 (42.9)

 IgM

1 (100.0)

1 (100.0)

0 (0.0)

1 (100.0)

1 (100.0)

0 (0.0)

0 (0.0)

1 (100.0)

1 (100.0)

1 (100.0)

 IgD

2 (100.0)

1 (50.0)

1 (50.0)

1 (50.0)

1 (50.0)

1 (50.0)

1 (50.0)

0 (0.0)

1 (50.0)

2 (100.0)

 Bence-Jones protein

11 (100.0)

6 (54.5)

6 (54.5)

7 (63.6)

4 (36.4)

6 (54.5)

5 (45.5)

2 (18.2)

4 (36.4)

5 (45.5)

 P value

0.451

0.875

0.310

0.291

0.689

0.603

0.670

0.038

0.746

0.497

Bone lesion, No. (%)

 No

8 (44.4)

9 (50.0)

9 (50.0)

8 (44.4)

7 (38.9)

10 (55.6)

11 (61.1)

11 (61.1)

8 (44.4)

11 (61.1)

 Yes

22 (52.4)

21 (50.0)

21 (50.0)

22 (52.4)

24 (57.1)

20 (47.6)

19 (45.2)

19 (45.2)

22 (52.4)

19 (45.2)

 P value

0.573

1.000

1.000

0.573

0.195

0.573

0.260

0.260

0.573

0.260

Hb, No. (%)

  < 10 g/dL

12 (44.4)

12 (44.4)

14 (51.9)

14 (51.9)

14(51.9)

11 (40.7)

14 (51.9)

13 (48.1)

11 (40.7)

14 (51.9)

  ≥ 10 g/dL

18 (54.5)

18 (54.5)

16 (48.5)

16 (48.5)

17 (51.5)

19 (57.6)

16 (48.5)

17 (51.5)

19 (57.6)

16 (48.5)

 P value

0.436

0.436

0.795

0.795

0.979

0.194

0.795

0.795

0.194

0.795

Calcium, No. (%)

  < 11.5 mg/dL

22 (52.4)

23 (54.8)

21 (50.0)

22 (52.4)

21 (50.0)

19 (45.2)

21 (50.0)

21 (50.0)

19 (45.2)

21 (50.0)

  ≥ 11.5 mg/dL

8 (44.4)

7 (38.9)

9 (50.0)

8 (44.4)

10 (55.6)

11 (61.1)

9 (50.0)

9 (50.0)

11 (61.1)

9 (50.0)

 P value

0.573

0.260

1.000

0.573

0.693

0.260

1.000

1.000

0.260

1.000

Scr, No. (%)

  < 2 mg/dL

26 (54.2)

22 (45.8)

25 (52.1)

23 (47.9)

23 (47.9)

26 (54.2)

25 (52.1)

23 (47.9)

26 (54.2)

26 (54.2)

  ≥ 2 mg/dL

4 (33.3)

8 (66.7)

5 (41.7)

7 (58.3)

8 (66.7)

4 (33.3)

5 (41.7)

7 (58.3)

4 (33.3)

4 (33.3)

 P value

0.197

0.197

0.519

0.519

0.245

0.197

0.519

0.519

0.197

0.197

ALB, No. (%)

  < 3.5 mg/dL

11 (57.9)

10 (52.6)

9 (47.4)

9 (47.4)

9 (47.4)

8 (42.1)

14 (73.7)

12 (63.2)

7 (36.8)

12 (63.2)

  ≥ 3.5 mg/dL

19 (46.3)

20 (48.8)

21 (51.2)

21 (51.2)

22 (53.7)

22 (53.7)

16 (39.0)

18 (43.9)

23 (56.1)

18 (43.9)

 P value

0.405

0.781

0.781

0.781

0.650

0.405

0.012

0.165

0.165

0.165

β2-MG, No. (%)

  < 5.5 mg/L

23 (67.6)

16 (47.1)

19 (55.9)

20 (58.8)

20 (58.8)

16 (47.1)

18 (52.9)

16 (47.1)

19 (55.9)

20 (58.8)

  ≥ 5.5 mg/L

7 (26.9)

14 (53.8)

11 (42.3)

10 (38.5)

11 (42.3)

14 (53.8)

12 (46.2)

14 (53.8)

11 (42.3)

10 (38.5)

 P value

0.002

0.602

0.297

0.118

0.205

0.602

0.602

0.602

0.297

0.118

LDH, No. (%)

  < 220 U/L

24 (51.1)

24 (51.1)

24 (51.1)

23 (48.9)

26 (55.3)

27 (57.4)

21 (44.7)

22 (46.8)

24 (51.1)

25 (53.2)

  ≥ 220 U/L

6 (46.2)

6 (46.2)

6 (46.2)

7 (53.8)

5 (38.5)

3 (23.1)

9 (69.2)

8 (61.5)

6 (46.2)

5 (38.5)

 P value

0.754

0.754

0.754

0.754

0.282

0.028

0.117

0.347

0.754

0.347

Durie-Salmon stage, No. (%)

 I/II

19 (55.9)

21 (61.8)

18 (52.9)

19 (55.9)

17 (50.0)

14 (41.2)

16 (47.1)

19 (55.9)

17 (50.0)

14 (41.2)

 III

11 (42.3)

9 (34.6)

12 (46.2)

11 (42.3)

14 (53.8)

16 (61.5)

14 (53.8)

11 (42.3)

13 (50.0)

16 (61.5)

 P value

0.297

0.037

0.602

0.297

0.768

0.118

0.602

0.297

1.000

0.118

ISS stage, No. (%)

 I/II

23 (67.6)

16 (47.1)

19 (55.9)

20 (58.8)

20 (58.8)

16 (47.1)

18 (52.9)

16 (47.1)

19 (55.9)

20 (58.8)

 III

7 (26.9)

14 (53.8)

11 (42.3)

10 (38.5)

11 (42.3)

14 (53.8)

12 (46.2)

14 (53.8)

11 (42.3)

10 (38.5)

 P value

0.002

0.602

0.297

0.118

0.205

0.602

0.602

0.602

0.297

0.118

t (4; 14), No. (%)

 No

29 (53.7)

25 (46.3)

25 (46.3)

28 (51.9)

27 (50.0)

26 (48.1)

27 (50.0)

27 (50.0)

27 (50.0)

26 (48.1)

 Yes

1 (16.7)

5 (83.3)

5 (83.3)

2 (33.3)

4 (66.7)

4 (66.7)

3 (50.0)

3 (50.0)

3 (50.0)

4 (66.7)

 P value

0.085

0.085

0.085

0.389

0.438

0.389

1.000

1.000

1.000

0.389

t (14; 16), No. (%)

 No

28 (52.8)

28 (52.8)

27 (50.9)

28 (52.8)

28 (52.8)

27 (50.9)

25 (47.2)

26 (49.1)

28 (52.8)

26 (49.1)

 Yes

2 (28.6)

2 (28.6)

3 (42.9)

2 (28.6)

3 (42.9)

3 (42.9)

5 (71.4)

4 (57.1)

2 (28.6)

4 (57.1)

 P value

0.228

0.228

0.688

0.228

0.620

0.688

0.228

0.688

0.228

0.688

Del (17p), No. (%)

 No

29 (52.7)

29 (52.7)

28 (50.9)

28 (50.9)

31 (56.4)

27 (49.1)

26 (47.3)

27 (49.1)

27 (49.1)

28 (50.9)

 Yes

1 (20.0)

1 (20.0)

2 (40.0)

2 (40.0)

0 (0.0)

3 (60.0)

4 (80.0)

3 (60.0)

3 (60.0)

2 (40.0)

 P value

0.161

0.161

0.640

0.640

0.016

0.640

0.161

0.640

0.640

0.640

  1. Comparisons were determined by Chi-square test. P value < 0.05 was considered significant. circRNAs circular RNAs, Ig immunoglobulin, Hb hemoglobin, Scr serum creatinine, ALB albumin, β2-MG β2-microglobulin, LDH lactate dehydrogenase, ISS international staging system. The number in boldface represented statistically significant P values
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us